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What is the best approach 
for patients with ASCUS
detected on Pap smear?
■ EVIDENCE-BASED ANSWER
DNA testing for human papillomavirus (HPV),
especially if the sample can be obtained at the
same time as the Papanicolaou (Pap) smear, can
guide the management of women whose test
result shows atypical squamous cells of undeter-
mined significance (ASCUS). Those who test
positive for high-risk types of HPV should be
referred for colposcopy (strength of recommen-
dation [SOR]: B), and those with a negative test
result may resume regular Pap testing in 12
months (SOR: B). If HPV testing is unavailable,
an alternative strategy is to repeat the Pap
smear at 4- to 6-month intervals. After 2 nega-
tive Pap smears are obtained, usual screening
may resume. But if either of the repeat Pap
smears results in ASCUS or worse, the woman
should be referred for colposcopy (SOR: B).
■ EVIDENCE SUMMARY
Although only 5% to 10% of women with the result
of ASCUS on a Pap smear have a high-grade squa-
mous intraepithelial lesion (HSIL), estimates sug-
gest that more than one third of these lesions are
identified during follow-up to ASCUS Pap smears.1
The recent ASCUS-LSIL Triage Study (ALTS), a
multicenter randomized trial, directly addressed
the appropriate evaluation of ASCUS.2 The trial
compared 3 management strategies for ASCUS
Pap smears: reflex HPV-DNA testing (the initial
Pap sample is tested for HPV only if the results are
ASCUS), immediate referral for colposcopy, and
repeat Pap smears. Reflex HPV testing had a sen-
sitivity of 96% for detecting HSIL and a negative
predictive value of 98%. The 44% of women
with ASCUS who tested negative for high-risk
HPV were able to avoid colposcopy. A single
repeat Pap smear within 4 to 6 months, with
referral for colposcopy if abnormal, had a sensi-
tivity of 85% (sensitivity might be expected to
improve with a second repeat test) and a similar
colposcopy referral rate.2
A cost-effectiveness analysis that modeled
data from the trial found that reflex HPV testing
was most cost-effective.3 For women aged 29
years or older, HPV testing resulted in a much
lower colposcopy referral rate, 31% vs 65% for
younger women, without sacrificing sensitivity.4
■ RECOMMENDATIONS FROM OTHERS
Evidenced-based guidelines were developed at 
a consensus conference sponsored by the
American Society for Colposcopy and Cervical
Pathology in September 2001.5 Recommen-
dations were also made for women with ASCUS
in special circumstances. Pregnant women
should be managed the same way as nonpregnant
women; immunosuppressed women should be
referred for colposcopy; and postmenopausal
women, who are at a lower risk for HSIL, may try
a 3- to 6-week course of intravaginal estrogen fol-
lowed by repeat Pap smears 1 week after estro-
gen treatment and again 4 to 6 months later. 
If either repeat test is reported as ASCUS or
greater, the woman should be referred for col-
poscopy. Any woman with a Pap smear reported
as ASCH (atypical squamous cells, cannot
exclude HSIL) should be referred for colposcopy.5
The US Preventive Services Task Force
recently concluded that evidence is insufficient to
recommend for or against the routine use of HPV
testing as a primary screening test for cervical
cancer, but they did not address the management
of abnormal Pap smears.6
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■ CLINICAL COMMENTARY
Thin-prep Pap smears can make workup
of ASCUS easier for physician and patient
The management of ASCUS Pap smears has
often confused primary care doctors. This is
confounded by the fact that it is often a chal-
lenge to ensure that patients follow our recom-
mendations. How could we blame them—after
all, who wants to undergo 4 Pap smears
instead of 1? The advent of thin-prep Pap
smears, with reflex HPV testing on the same
specimen, has simplified our lives. By obtain-
ing routine thin-prep Pap smears and then
reflex HPV testing for only high-risk HPV
types, fewer Pap smears and colposcopic
exams are needed, without reducing the detec-
tion of HSIL. Best of all, fewer women are
overtreated or lost to follow-up.
John Hill, MD, University of Colorado Health Sciences
Center, Denver
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Are ARBs or ACE inhibitors
preferred for nephropathy 
in diabetes?
■ EVIDENCE-BASED ANSWER
Angiotensin receptor blockers (ARBs) have been
shown to reduce the progression of nephropathy
in several consistent studies. While ACE
inhibitors have not been as well studied for the
endpoint of nephropathy, patients with nephropa-
thy exhibit reduced mortality when treated with
an ACE inhibitor (strength of recommendation:
A, based on randomized controlled trials).
■ EVIDENCE SUMMARY
The RENAAL (Reduction of Endpoints in
NIDDM with the Angiotensin II Antagonist
Losartan) study1—a multicenter, randomized,
double-blind, placebo-controlled trial—followed
1513 patients with type 2 diabetes and nephropa-
thy over a mean of 3.4 years. Patients were 
randomized to receive losartan (Cozaar) or 
placebo, both taken in addition to conventional
anti-hypertensive therapy (but not including 
renin-angiotensin-aldosterone system antagonist
medications). The primary outcome was a compos-
ite of a doubling of serum creatinine, end-stage
renal disease, or death. The number needed to treat
(NNT) for the composite outcome was 34. The NNT
for a doubling of the serum creatinine was 25, and
for end-stage renal disease was 17.
The 2-year IRMA (Irbesartan Microalbumin-
uria) study,2 a multicenter, randomized, double-
blind, placebo-controlled trial, randomized 590
patients with type 2 diabetes, hypertension, and
persistent microalbuminuria to receive 150 or 300
mg of irbesartan (Avapro) or placebo. Additional
antihypertensive agents were allowed in each arm
with the exception of ACE inhibitors, ARBs, and
dihydropyridine calcium-channel blockers. The
primary outcome was the development of overt
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